Literature DB >> 20944037

Rebuttal: palivizumab for the prevention of respiratory syncytial virus infection.

Kelly A Smart, Krista L Lanctôt, Bosco A Paes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20944037      PMCID： PMC2954075     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


× No keyword cloud information.
  24 in total

1.  Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: What are we trying to prevent?

Authors:  B Law; N Macdonald; J Langley; I Mitchell; D Stephens; E Wang; J Robinson; F Boucher; J McDonald; S Dobson
Journal:  Paediatr Child Health       Date:  1998-11       Impact factor: 2.253

2.  Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation.

Authors:  John S Sampalis; Joanne Langley; Xavier Carbonell-Estrany; Bosco Paes; Karel O'Brien; Upton Allen; Ian Mitchell; José Figueras Aloy; Carmen Pedraz; Andrea F Michaliszyn
Journal:  Med Decis Making       Date:  2008-06-12       Impact factor: 2.583

3.  Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis.

Authors:  Mark J C Nuijten; Wolfgang Wittenberg; Maximilian Lebmeier
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

4.  Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.

Authors: 
Journal:  Pediatrics       Date:  1998-09       Impact factor: 7.124

Review 5.  The cost effectiveness of palivizumab: a systematic review of the evidence.

Authors:  Kelly A Smart; Krista L Lanctôt; Bosco A Paes
Journal:  J Med Econ       Date:  2010       Impact factor: 2.448

6.  Prevention of respiratory syncytial virus infection.

Authors:  L Samson
Journal:  Paediatr Child Health       Date:  2009-10       Impact factor: 2.253

7.  Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.

Authors:  Carole A Reeve; John S Whitehall; Petra G Buettner; Robert Norton; David M Reeve; Fleur Francis
Journal:  J Paediatr Child Health       Date:  2006-05       Impact factor: 1.954

8.  The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis .

Authors:  Krista L Lanctôt; Shababa T Masoud; Bosco A Paes; Jean-Eric Tarride; Aaron Chiu; Charles Hui; Philip L Francis; Paul I Oh
Journal:  Curr Med Res Opin       Date:  2008-10-16       Impact factor: 2.580

9.  The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation.

Authors:  Barbara J Law; Joanne M Langley; Upton Allen; Bosco Paes; David S C Lee; Ian Mitchell; John Sampalis; Hervé Walti; Joan Robinson; Karel O'Brien; Carina Majaesic; Georges Caouette; Lyne Frenette; Nicole Le Saux; Brian Simmons; Sharon Moisiuk; Koravanagattu Sankaran; Cecil Ojah; Avash J Singh; Marc H Lebel; Godfrey S Bacheyie; Heather Onyett; Andrea Michaliszyn; Patricia Manzi; Diana Parison
Journal:  Pediatr Infect Dis J       Date:  2004-09       Impact factor: 2.129

10.  Complications in infants hospitalized for bronchiolitis or respiratory syncytial virus pneumonia.

Authors:  Douglas F Willson; Christopher P Landrigan; Susan D Horn; Randall J Smout
Journal:  J Pediatr       Date:  2003-11       Impact factor: 4.406
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.